ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...

The company noted that its Phase 2 community study, known as POSITS, has started with the first participants being dosed in ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Vizhinjam port Phase-2 inauguration gains political significance as Kerala government showcases development ahead of Assembly ...

The MarketWatch News Department was not involved in the creation of this content. Dubai, UAE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The DeFi market is witnessing renewed attention as projects with use ...

Mutuum Finance (MUTM) has reported progress on its development roadmap as the project prepares for the release of its V1 ...